Literature DB >> 23271737

Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.

Jeff A O'Meara1, Christopher T Lemke, Cédrickx Godbout, George Kukolj, Lisette Lagacé, Benoît Moreau, Diane Thibeault, Peter W White, Montse Llinàs-Brunet.   

Abstract

Although optimizing the resistance profile of an inhibitor can be challenging, it is potentially important for improving the long term effectiveness of antiviral therapy. This work describes our rational approach toward the identification of a macrocyclic acylsulfonamide that is a potent inhibitor of the NS3-NS4A proteases of all hepatitis C virus genotypes and of a panel of genotype 1-resistant variants. The enhanced potency of this compound versus variants D168V and R155K facilitated x-ray determination of the inhibitor-variant complexes. In turn, these structural studies revealed a complex molecular basis of resistance and rationalized how such compounds are able to circumvent these mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271737      PMCID: PMC3581377          DOI: 10.1074/jbc.M112.439455

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes.

Authors:  S Di Marco; M Rizzi; C Volpari; M A Walsh; F Narjes; S Colarusso; R De Francesco; V G Matassa; M Sollazzo
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

2.  The finer things in X-ray diffraction data collection.

Authors:  J W Pflugrath
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-10

3.  Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.

Authors:  Youla S Tsantrizos; Gordon Bolger; Pierre Bonneau; Dale R Cameron; Nathalie Goudreau; George Kukolj; Steven R LaPlante; Montse Llinàs-Brunet; Herbert Nar; Daniel Lamarre
Journal:  Angew Chem Int Ed Engl       Date:  2003-03-28       Impact factor: 15.336

4.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

5.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

6.  Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.

Authors:  J L Kim; K A Morgenstern; C Lin; T Fox; M D Dwyer; J A Landro; S P Chambers; W Markland; C A Lepre; E T O'Malley; S L Harbeson; C M Rice; M A Murcko; P R Caron; J A Thomson
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

7.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

Authors:  Holger Hinrichsen; Yves Benhamou; Heiner Wedemeyer; Markus Reiser; Roel E Sentjens; José L Calleja; Xavier Forns; Andreas Erhardt; Jens Crönlein; Ricardo L Chaves; Chan-Loi Yong; Gerhard Nehmiz; Gerhard G Steinmann
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Visual detection of peptidase activity using fluorogenic substrates in a microtiter plate assay.

Authors:  G B Irvine; M Ennis; C H Williams
Journal:  Anal Biochem       Date:  1990-03       Impact factor: 3.365

9.  Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

Authors:  Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Maurice; Peter W White; Daniel Lamarre
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.

Authors:  Keith P Romano; Akbar Ali; Cihan Aydin; Djade Soumana; Ayşegül Ozen; Laura M Deveau; Casey Silver; Hong Cao; Alicia Newton; Christos J Petropoulos; Wei Huang; Celia A Schiffer
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

View more
  5 in total

1.  Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.

Authors:  Ashley N Matthew; Jacqueto Zephyr; Caitlin J Hill; Muhammad Jahangir; Alicia Newton; Christos J Petropoulos; Wei Huang; Nese Kurt-Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2017-06-19       Impact factor: 7.446

2.  Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.

Authors:  Ashley N Matthew; Florian Leidner; Alicia Newton; Christos J Petropoulos; Wei Huang; Akbar Ali; Nese KurtYilmaz; Celia A Schiffer
Journal:  Structure       Date:  2018-08-23       Impact factor: 5.006

3.  Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

Authors:  Djadé I Soumana; Nese Kurt Yilmaz; Akbar Ali; Kristina L Prachanronarong; Celia A Schiffer
Journal:  J Am Chem Soc       Date:  2016-09-02       Impact factor: 15.419

Review 4.  Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

Authors:  Ashley N Matthew; Florian Leidner; Gordon J Lockbaum; Mina Henes; Jacqueto Zephyr; Shurong Hou; Desaboini Nageswara Rao; Jennifer Timm; Linah N Rusere; Debra A Ragland; Janet L Paulsen; Kristina Prachanronarong; Djade I Soumana; Ellen A Nalivaika; Nese Kurt Yilmaz; Akbar Ali; Celia A Schiffer
Journal:  Chem Rev       Date:  2021-01-07       Impact factor: 60.622

5.  Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.

Authors:  Ashley N Matthew; Jacqueto Zephyr; Desaboini Nageswara Rao; Mina Henes; Wasih Kamran; Klajdi Kosovrasti; Adam K Hedger; Gordon J Lockbaum; Jennifer Timm; Akbar Ali; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  mBio       Date:  2020-03-31       Impact factor: 7.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.